Metabolic complications in acromegaly after neurosurgery: A meta-analysis.

in European Journal of Endocrinology
View More View Less
  • 1 A Cozzolino, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 2 T Feola, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 3 I Simonelli, Medical Statistics and Information Technology, AFaR-Fatebenefratelli Hospital, Rome, Italy
  • 4 G Puliani, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 5 V Hasenmajer, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 6 M Minnetti, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 7 E Giannetta, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 8 D Gianfrilli, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 9 P Pasqualetti, Medical Statistics and Information Technology, AFaR-Fatebenefratelli Hospital, Rome, Italy
  • 10 A Lenzi, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
  • 11 A Isidori, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy

Correspondence: Andrea Isidori, Email: andrea.isidori@uniroma1.it
Restricted access

Objective: Neurosurgery is the first-line treatment for acromegaly. Whether metabolic disorders are reversible after neurosurgery is still debated. The meta-analysis aimed to address the following questions: 1) Does neurosurgery affect glycolipid metabolism? 2) Are these effects related to disease control or follow-up length?

Design: a meta-analysis and systematic review of the literature.

Methods: Three reviewers searched up databases until August 2019 for prospective trials reporting glycometabolic outcomes after neurosurgery. Three other extracted outcomes, all assessed the risk of bias.

Results: Twenty studies were included. Neurosurgery significantly reduced fasting plasma glucose (FPG) [effect size (ES) -0.57 mmol/L, 95% CI -0.82 to -0.31; P<0.001], glucose load [ES -1.10 mmol/L, 95% CI -1.66 to -0.53; p<0.001], glycosylated haemoglobin (HbA1c) [ES -0.28%, 95% CI -0.42 to -0.14; P<0.001], fasting plasma insulin (FPI) [ES -10.53 mU/L, 95% CI -14.54 to -6.51; P<0.001], homeostatic model assessment of insulin resistance (HOMA-IR) [ES -1.98, 95% CI -3.24 to -0.72; P=0.002], triglycerides (TGDs) [ES -0.28 mmol/L, 95% CI -0.36 to -0.20; P<0.001] and LDL-cholesterol (LDL-C) [ES -0.23 mmol/L, 95% CI -0.45 to -0.02 mmol/L); P=0.030] and increased HDL-cholesterol (HDL-C) [ES 0.21 mmol/L, 95% CI 0.14 to 0.28; P<0.001]. Meta-regression analysis showed that follow-up length - not disease control - had a significant effect on FPG, with the greatest reduction in the shortest follow-up (beta=0.012, SE=0.003; P=0.001).

Conclusions: Neurosurgery improves metabolism with a significant decrease in FPG, glucose load, HbA1c, FPI, HOMA-IR, TGDs, and LDL-C and increase in HDL-C. The effect on FPG seems to be more related to follow-up length than to disease control.

 

     European Society of Endocrinology